REG - ReNeuron Group plc - Notice of Results

ReNeuronAnnouncement

18/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230518:nRSR7909Za&default-theme=true

RNS Number : 7909Z  ReNeuron Group plc  18 May 2023

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Notice of Results

Investor presentation

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived
exosome technologies, will announce its preliminary results for the year ended
31 March 2023 on Thursday 25 May 2023.

 

Investor Briefing

Management will also be hosting a live online presentation relating to the
preliminary results via the Investor Meet Company platform at 9:30am BST on
Thursday 25 May 2023. The presentation is open to all existing and potential
shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here:

https://www.investormeetcompany.com/reneuron-group-plc/register-investor
(https://www.investormeetcompany.com/reneuron-group-plc/register-investor)

 

Investors who already follow ReNeuron on the Investor Meet Company platform
will automatically be invited.

 

Questions can be submitted pre-event via your IMC dashboard or in real time
during the presentation, via the "Ask a Question" function.  Whilst the
Company may not be in a position to answer every question it receives, it will
address the most prominent within the confines of information already
disclosed to the market through regulatory notifications. A recording of the
presentation, a PDF of the slides used, and responses to the Q&A session
will be available on the Investor Meet Company platform afterwards.

 

 

ENDS

Enquiries:

 

 ReNeuron                                                           www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Executive Chairman                                      Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Allenby Capital Limited (Nominated Adviser and Broker)             +44 (0)20 3328 5656
 James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                           +44 (0)20 7933 8780
 Paul McManus / Alice Woodings                                      or reneuron@walbrookpr.com (mailto:reneuron@walbrookpr.com)
                                                                    +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.

 

Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Company can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORQDLFFXELEBBE